SJIF(2020): 5.702

International Journal of Advanced Research and Publications

High Quality Publications & World Wide Indexing!

The Role Of Probiotics In The Treatment Of Helicobacter Pylori-Caused Gastritis

Volume 5 - Issue 3, March 2022 Edition
[Download Full Paper]

Zerihun Asefa Biru
Duodenum, Gastritis, Helicobacter pylori, Probiotics, Ulcer.
Helicobacter pylori are a typical bacterium that affects a portion of the population in the world. Probiotics in combination with antibiotics to treat gastritis caused by Helicobacter pylori is an effective treatment that has fewer negative effects than antibiotics alone. In comparison to using antibiotics alone, probiotics plus antibiotic supplementation eliminate gastritis caused by H pylori. Antibiotic-based H. pylori treatment is only about seventy percent successful, and it comes with a slew of side effects. As a result, probiotics combined with antibiotics have a completely inhibiting effect on H. pylori caused by gastritis. Probiotics are beneficial in reducing H. pylori-related stomach discomfort, according to several in vivo investigations. Human studies looked at the efficacy of antibiotics and probiotics in combination, and the results showed that probiotics improved H. pylori gastritis reduction and inhibited H. pylori settlement. Despite this, no study has been able to show that probiotics alone are capable of eliminating H. pylori. Probiotics used in conjunction with antibiotics can reduce the antagonistic qualities induced by H. pylori abolition antibiotic activity, and hence have beneficial properties in H. pylori-infected people. Long-term intake of diets containing probiotic strains improves antibiotic action of H. pylori infection in humans, mostly by lowering the risk of antibiotic-related diseases.
[1]. Kusters, J.G., A.H. Van Vliet, and E.J. Kuipers, Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews, 2006. 19(3): p. 449-490.

[2]. Stamatis, G., et al., In vitro anti-Helicobacter pylori activity of Greek herbal medicines. Journal of ethnopharmacology, 2003. 88(2-3): p. 175-179.

[3]. Shin, I.S., H. Masuda, and K. Naohide, Bactericidal activity of wasabi (Wasabia japonica) against Helicobacter pylori. International Journal of Food Microbiology, 2004. 94(3): p. 255-261.

[4]. Erim, T., et al., Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World journal of surgery, 2008. 32(9): p. 2021-2025.

[5]. Uemura, N. and S. Okamoto, Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterology Clinics of North America, 2000. 29(4): p. 819-827.

[6]. Dooley, C.P., et al., Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. New England journal of medicine, 1989. 321(23): p. 1562-1566.

[7]. Kashiwagi, H., Ulcers and gastritis. Endoscopy, 2003. 35(01): p. 9-14.

[8]. Plummer, M., S. Franceschi, and N. Muñoz, Epidemiology of gastric cancer. IARC scientific publications, 2004(157): p. 311-326.

[9]. Ohata, H., et al., Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. International journal of cancer, 2004. 109(1): p. 138-143.

[10]. Frenck Jr, R.W. and J. Clemens, Helicobacter in the developing world. Microbes and infection, 2003. 5(8): p. 705-713.

[11]. Rothenbacher, D. and H. Brenner, Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes and Infection, 2003. 5(8): p. 693-703.

[12]. Aguemon, B., et al., Prevalence and risk-factors for Helicobacter pylori infection in urban and rural Beninese populations. Clinical microbiology and infection, 2005. 11(8): p. 611-617.

[13]. Syam, A.F., et al., Risk factors and prevalence of Helicobacter pylori in five largest islands of Indonesia: A preliminary study. PloS one, 2015. 10(11): p. e0140186.

[14]. Brigitte, S., et al., RNA interactomics: recent advances and remaining challenges. F1000Research, 2018. 7.

[15]. Vaira, D., et al., The transmission of Helicobacter pylori from stomach to stomach. Alimentary Pharmacology & Therapeutics, 2001. 15: p. 33-42.

[16]. Weyermann, M., et al., The mother as source of Helicobacter pylori infection. Epidemiology, 2006: p. 332-334.

[17]. Hemaiswarya, S., et al., Mechanism of action of probiotics. Brazilian archives of Biology and technology, 2013. 56(1): p. 113-119.

[18]. Malfertheiner, P., et al., Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report. Alimentary pharmacology & therapeutics, 2002. 16(2): p. 167-180.

[19]. Peyrin–Biroulet, L., et al., Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology, 2008. 6(6): p. 644-653.

[20]. Gerrits, M.M., et al., Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. The Lancet infectious diseases, 2006. 6(11): p. 699-709.

[21]. Logan, R.P. and M.M. Walker, ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ: British Medical Journal, 2001. 323(7318): p. 920.

[22]. Gatta, G., et al., Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. European journal of cancer, 2003. 39(15): p. 2214-2222.

[23]. Lionetti, E., et al., Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter, 2010. 15(2): p. 79-87.

[24]. Balcázar, J.L., et al., The role of probiotics in aquaculture. Veterinary microbiology, 2006. 114(3-4): p. 173-186.

[25]. Malfertheiner, P., et al., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007. 56(6): p. 772-781.

[26]. Broutet, N., et al., Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients. Alimentary pharmacology & therapeutics, 2003. 17(1): p. 99-109.

[27]. Grajek, W., A. Olejnik, and A. Sip, Probiotics, prebiotics and antioxidants as functional foods. Acta Biochimica Polonica, 2005. 52(3): p. 665-671.

[28]. Tanih, N., et al., Helicobacter pylori infection in Africa: Pathology and microbiological diagnosis. African Journal of Biotechnology, 2008. 7(25).

[29]. Chauviere, G., et al., Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. Microbiology, 1992. 138(8): p. 1689-1696.

[30]. Mitchell, P., et al., Helicobacter pylori induces in-vivo expansion of human regulatory T cells through stimulating interleukin-1β production by dendritic cells. Clinical & Experimental Immunology, 2012. 170(3): p. 300-309.

[31]. Coconnier, M.-H., et al., Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Applied and Environmental Microbiology, 1998. 64(11): p. 4573-4580.

[32]. Chey, W.D., B.C. Wong, and P.P.C.o.t.A.C.o. Gastroenterology, American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Official journal of the American College of Gastroenterology| ACG, 2007. 102(8): p. 1808-1825.

[33]. Graham, D.Y. and L. Fischbach, Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 2010. 59(8): p. 1143-1153.

[34]. Malfertheiner, P., et al., Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet, 2011. 377(9769): p. 905-913.

[35]. Vítor, J.M. and F.F. Vale, Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunology & Medical Microbiology, 2011. 63(2): p. 153-164.

[36]. Zullo, A., et al., Effects of Helicobacter pylori eradication on early stage gastric mucosa–associated lymphoid tissue lymphoma. Clinical gastroenterology and hepatology, 2010. 8(2): p. 105-110.

[37]. Wu, C.-Y., et al., Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology, 2010. 28(18).

[38]. Iqbal, M.Z., et al., Probiotics and their beneficial effects against various diseases. Pakistan journal of pharmaceutical sciences, 2014. 27(2).

[39]. Gotteland, M., O. Brunser, and S. Cruchet, Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Alimentary pharmacology & therapeutics, 2006. 23(8): p. 1077-1086.

[40]. Wilhelm, S.M., J.L. Johnson, and P.B. Kale-Pradhan, Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Annals of Pharmacotherapy, 2011. 45(7-8): p. 960-966.

[41]. Lü, M., et al., Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PloS one, 2016. 11(10): p. e0163743.

[42]. Mohan, B.P., et al., Convolutional neural networks in the computer-aided diagnosis of Helicobacter pylori infection and non-causal comparison to physician endoscopists: a systematic review with meta-analysis. Annals of gastroenterology, 2021. 34(1): p. 20.

[43]. Klaenhammer, T.R., Genetics of bacteriocins produced by lactic acid bacteria. FEMS microbiology reviews, 1993. 12(1-3): p. 39-85.

[44]. Ohland, C.L. and W.K. MacNaughton, Probiotic bacteria and intestinal epithelial barrier function. American journal of physiology-gastrointestinal and liver physiology, 2010. 298(6): p. G807-G819.

[45]. Hooper, L.V., et al., Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nature immunology, 2003. 4(3): p. 269-273.

[46]. Hummel, T.Z., et al., Additional value of upper GI tract endoscopy in the diagnostic assessment of childhood IBD. Journal of pediatric gastroenterology and nutrition, 2012. 54(6): p. 753-757.

[47]. Dai, S., et al., Effects of lactic acid bacteria‐fermented soymilk on isoflavone metabolites and short‐chain fatty acids excretion and their modulating effects on gut microbiota. Journal of food science, 2019. 84(7): p. 1854-1863.

[48]. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology, 2006. 3(7): p. 390-407.

[49]. Bermudez-Brito, M., et al., Probiotic mechanisms of action. Annals of Nutrition and Metabolism, 2012. 61(2): p. 160-174.

[50]. Mack, D.R., et al., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut, 2003. 52(6): p. 827-833.

[51]. Otte, J.-M., E. Cario, and D.K. Podolsky, Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology, 2004. 126(4): p. 1054-1070.

[52] Schiffrin, E.L., M.L. Lipman, and J.F. Mann, Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007. 116(1): p. 85-97.

[53]. González-Rodríguez, I., et al., Role of extracellular transaldolase from Bifidobacterium bifidum in mucin adhesion and aggregation. Applied and environmental microbiology, 2012. 78(11): p. 3992-3998.

[54]. Neutra, M., Gastrointestinal mucus: synthesis, secretion, and function. Physiology of the gastrointestinal tract, 1987: p. 975-1009.

[55]. Mukherjee, S., et al., Quantitative appraisal of the probiotic attributes and in vitro adhesion potential of anti-listerial bacteriocin-producing lactic acid bacteria. Probiotics and antimicrobial proteins, 2013. 5(2): p. 99-109.

[56]. Vélez, M.P., et al., Identification and characterization of starter lactic acid bacteria and probiotics from Columbian dairy products. Journal of Applied Microbiology, 2007. 103(3): p. 666-674.

[57]. Sanchez, M., et al., Effect of Lactobacillus rhamnosus CGMCC1. 3724 supplementation on weight loss and maintenance in obese men and women. British Journal of Nutrition, 2014. 111(8): p. 1507-1519.

[58]. Candela, M., et al., Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. International journal of food microbiology, 2008. 125(3): p. 286-292.

[59]. Ouwehand, A.C., S. Salminen, and E. Isolauri, Probiotics: an overview of beneficial effects. Lactic acid bacteria: genetics, metabolism and applications, 2002: p. 279-289.

[60]. Kim, E.K. and E.-J. Choi, Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2010. 1802(4): p. 396-405.

[61]. Caballero-Franco, C., et al., The VSL# 3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2007. 292(1): p. G315-G322.

[62]. Furrie, E., Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome? Nature Clinical Practice Gastroenterology & Hepatology, 2005. 2(7): p. 304-305.

[63]. Bals, A. and U. Kulozik, The influence of the pore size, the foaming temperature and the viscosity of the continuous phase on the properties of foams produced by membrane foaming. Journal of Membrane Science, 2003. 220(1-2): p. 5-11.

[64]. Mukai, A., et al., Nocardithiocin, a novel thiopeptide antibiotic, produced by pathogenic Nocardia pseudobrasiliensis IFM 0757. The Journal of antibiotics, 2009. 62(11): p. 613-619.

[65]. Rolfe, G., D. Freshwater, and M. Jasper, Critical Reflection for Nursing and the Helping Professions a User's Guide. 2001.

[66]. Servin, A.L., Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS microbiology reviews, 2004. 28(4): p. 405-440.

[67]. Schiffrin, E. and S. Blum, Interactions between the microbiota and the intestinal mucosa. European journal of clinical nutrition, 2002. 56(3): p. S60-S64.

[68]. Fujiwara, M. and H. Caswell, Demography of the endangered North Atlantic right whale. Nature, 2001. 414(6863): p. 537-541.

[69] . Mukai, T., et al., Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology & Medical Microbiology, 2002. 32(2): p. 105-110.

[70]. Makras, L., et al., Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Research in Microbiology, 2006. 157(3): p. 241-247.

[71]. Russell, R., et al., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis international, 2008. 19(6): p. 733-759.

[72]. Hassan, S.F. and R.A. Rosen, Resolving the ghost problem in nonlinear massive gravity. Physical review letters, 2012. 108(4): p. 041101.

[73]. O'Shea, J.J. and R. Plenge, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity, 2012. 36(4): p. 542-550.

[74]. Lievin, V., et al., Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut, 2000. 47(5): p. 646-652.

[75]. Oelschlaeger, T.A., Mechanisms of probiotic actions–a review. International journal of medical microbiology, 2010. 300(1): p. 57-62.

[76]. van den Bergh, W.M., et al., Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery, 2003. 52(2): p. 276-282.

[77]. Vizoso Pinto, M.G., et al., LuMPIS–A modified luminescence‐based mammalian interactome mapping pull‐down assay for the investigation of protein–protein interactions encoded by GC‐low ORFs. Proteomics, 2009. 9(23): p. 5303-5308.

[78]. Nam, K.H. and J. Li, BRI1/BAK1, a receptor kinase pair mediating brassinosteroid signaling. Cell, 2002. 110(2): p. 203-212.

[79]. Kim, J., H.-K. Chung, and C. Chae, Association of porcine circovirus 2 with porcine respiratory disease complex. The Veterinary Journal, 2003. 166(3): p. 251-256.

[80]. Gómez-Llorente, C., S. Munoz, and A. Gil, Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proceedings of the Nutrition Society, 2010. 69(3): p. 381-389.

[81]. Lebeer, S., J. Vanderleyden, and S.C. De Keersmaecker, Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews Microbiology, 2010. 8(3): p. 171-184.

[82]. Miriam, M., Diminishing demandingness of parents; children with recurrent infections. Health, 2012. 2012.

[83]. Arakawa, T., Regulation of acid secretion and peptic ulcer formation by inflammatory cytokines. The Immunobiology of H. pylori-From Pathogenesis to Prevention, 1997. 183.

[84]. Goodyear-Smith, F., et al., Immunization in the print media—Perspectives presented by the press. Journal of health communication, 2007. 12(8): p. 759-770.

[85]. Johnston, N., et al., Cell biology of laryngeal epithelial defenses in health and disease: further studies. Annals of Otology, Rhinology & Laryngology, 2003. 112(6): p. 481-491.

[86]. Kabir, S., Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter, 2009. 14(3): p. 159-171.

[87]. Vitini, E., et al., Gut mucosal immunostimulation by lactic acid bacteria. Biocell: official journal of the Sociedades Latinoamericanas de Microscopia Electronica... et. al, 2000. 24(3): p. 223-232.

[88]. Haller, D., et al., Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut, 2000. 47(1): p. 79-87.